Ana Vivancos
About
Ana Vivancos is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Ana Vivancos has authored 135 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Oncology, 70 papers in Cancer Research and 54 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ana Vivancos's work include Cancer Genomics and Diagnostics (62 papers), Lung Cancer Treatments and Mutations (27 papers) and Colorectal Cancer Treatments and Studies (23 papers). Ana Vivancos is often cited by papers focused on Cancer Genomics and Diagnostics (62 papers), Lung Cancer Treatments and Mutations (27 papers) and Colorectal Cancer Treatments and Studies (23 papers). Ana Vivancos collaborates with scholars based in Spain, United States and Palestinian Territory. Ana Vivancos's co-authors include Josep Tabernero, Elena Hidalgo, Enriqueta Felip, José Ayté, Geoffrey R. Oxnard, J. Carl Barrett, Brian Dougherty, Byoung Chul Cho, Mireille Cantarini and Kenneth S. Thress and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Medicine.
In The Last Decade
Ana Vivancos
122 papers receiving 5.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ana Vivancos Spain | 34 | 2.9k | 2.0k | 1.6k | 1.6k | 597 | 135 | 5.2k | ||
| Katsuya Tsuchihara Japan | 38 | 2.9k 1.0× | 2.1k 1.0× | 1.6k 1.0× | 1.3k 0.8× | 417 0.7× | 148 | 5.1k | ||
| Antonella De Luca Italy | 38 | 3.6k 1.2× | 3.4k 1.7× | 1.4k 0.9× | 1.7k 1.1× | 619 1.0× | 102 | 6.8k | ||
| Joshua A. Bauer United States | 21 | 2.9k 1.0× | 3.3k 1.6× | 2.3k 1.4× | 1.4k 0.9× | 453 0.8× | 49 | 6.3k | ||
| David S. Shames United States | 45 | 3.0k 1.0× | 2.9k 1.4× | 1.9k 1.2× | 2.4k 1.5× | 455 0.8× | 110 | 6.1k | ||
| Shanker Kalyana‐Sundaram United States | 23 | 3.8k 1.3× | 875 0.4× | 1.6k 1.0× | 1.3k 0.8× | 337 0.6× | 30 | 5.1k | ||
| Paul D. Smith United Kingdom | 45 | 5.1k 1.7× | 2.4k 1.2× | 1.4k 0.9× | 1.4k 0.9× | 791 1.3× | 120 | 7.5k | ||
| Yun Wu United States | 36 | 2.1k 0.7× | 2.5k 1.2× | 1.8k 1.1× | 870 0.5× | 694 1.2× | 105 | 5.2k | ||
| Ron Bose United States | 33 | 3.5k 1.2× | 3.1k 1.5× | 1.2k 0.7× | 1.3k 0.8× | 596 1.0× | 94 | 6.7k | ||
| Miriam Martini Italy | 24 | 2.1k 0.7× | 2.4k 1.2× | 971 0.6× | 1.0k 0.6× | 1.1k 1.8× | 45 | 4.5k | ||
| Monica R. Maiello Italy | 23 | 2.4k 0.8× | 2.2k 1.1× | 775 0.5× | 1.1k 0.7× | 351 0.6× | 40 | 4.4k |
Countries citing papers authored by Ana Vivancos
Since
Specialization
Citations
This map shows the geographic impact of Ana Vivancos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana Vivancos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana Vivancos more than expected).
Fields of papers citing papers by Ana Vivancos
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ana Vivancos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana Vivancos. The network helps show where Ana Vivancos may publish in the future.
Co-authorship network of co-authors of Ana Vivancos
This figure shows the co-authorship network connecting the top 25 collaborators of Ana Vivancos. A scholar is included among the top collaborators of Ana Vivancos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana Vivancos. Ana Vivancos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Matito, Judit, María Quindós, Claudia Valverde, et al.. (2025). Targeted Next-Generation Sequencing in Succinate Dehydrogenase–Deficient GI Stromal Tumor Identifies Actionable Alterations in the PI3K/mTOR Pathway. JCO Precision Oncology. 9(9). e2400497–e2400497.
2.
Perachino, Marta, Carolina Ortiz, Javier Carmona, Cristina Saura, & Ana Vivancos. (2025). Expanding screening through the use of liquid biopsy for early cancer detection. Communications Medicine. 5(1). 167–167.
3.
Mirallas, Oriol, et al.. (2025). Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategies. Frontiers in Immunology. 16. 1664443–1664443.
4.
Villacampa, Guillermo, Tomás Pascual, Fara Brasó‐Maristany, et al.. (2024). Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B). ESMO Open. 9(3). 102388–102388.
5.
Usset, Joseph, Axel Rosendahl Huber, Maria Andrianova, et al.. (2024). Five latent factors underlie response to immunotherapy. Nature Genetics. 56(10). 2112–2120.
6.
Carbonell, Caterina, Joan Frigola, Núria Pardo, et al.. (2023). Dynamic changes in circulating tumor DNA assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC . Molecular Oncology. 17(5). 779–791.
7.
Castet, Florian, Vı́ctor Navarro, Daniel Acosta, et al.. (2023). Clinical and genomic characterisation of early-onset pancreatic cancer. European Journal of Cancer. 194. 113338–113338.
8.
Chiaravalli, Marta, Anthony Turpin, Florian Castet, et al.. (2023). Clinical and genomic characterization of pancreatic ductal adenocarcinoma patients with lung oligometastasis. SHILAP Revista de lepidopterología. 2. 100011–100011.
9.
Vidal, Laura, Elizabeth Pando, L. Blanco, et al.. (2023). Liquid biopsy after resection of pancreatic adenocarcinoma and its relation to oncological outcomes. Systematic review and meta-analysis. Cancer Treatment Reviews. 120. 102604–102604.
10.
Guarneri, Valentina, Fara Brasó‐Maristany, Maria Vittoria Dieci, et al.. (2022). HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial. EBioMedicine. 85. 104320–104320.
11.
Palomero, Jara, Ana Vivancos, Carlos E. de Andrea, et al.. (2022). Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer.. Journal for ImmunoTherapy of Cancer. 10(12). e005443–e005443.
12.
Saura, Cristina, Judit Matito, Mafalda Oliveira, et al.. (2021). Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. Clinical Cancer Research. 27(21). 5818–5827.
13.
Verdaguer, Helena, Elvira Buxó, N. Saoudi Gonzalez, et al.. (2020). 1558P Pancreatic cancer (PC) in patients (pts) younger than 50 years: Clinical outcomes and actionable genomic/genetic alterations. Annals of Oncology. 31. S951–S951.
14.
Serna, Garazi, Franco Cecchi, Roberta Fasani, et al.. (2019). Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. Scientific Reports. 9(1). 13568–13568.
15.
Capdevila, Jaume, Oriol Arqués, José Ramón Hernández Mora, et al.. (2019). Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. Clinical Cancer Research. 26(4). 902–909.
16.
Capdevila, Jaume, Ignacio Matos, Francesco M. Mancuso, et al.. (2019). Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial. Molecular Cancer Therapeutics. 19(1). 312–317.
17.
Prat, Aleix, Alejandro Navarro, Laia Paré, et al.. (2017). Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. Cancer Research. 77(13). 3540–3550.
18.
Arqués, Oriol, Irene Chicote, Isabel Puig, et al.. (2015). Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clinical Cancer Research. 22(3). 644–656.
19.
Serra, Violeta, Ana Vivancos, Xosé S. Puente, et al.. (2013). Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2 V659E Mutation. Cancer Discovery. 3(11). 1238–1244.
20.
Rodón, Jordi, Cristina Saura, Rodrigo Dienstmann, et al.. (2012). Molecular prescreening to select patient population in early clinical trials. Nature Reviews Clinical Oncology. 9(6). 359–366.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Katsuya Tsuchihara Breakdown of academic impact, for papers by Antonella De Luca Breakdown of academic impact, for papers by Joshua A. Bauer Breakdown of academic impact, for papers by David S. Shames Breakdown of academic impact, for papers by Shanker Kalyana‐Sundaram Breakdown of academic impact, for papers by Paul D. Smith Breakdown of academic impact, for papers by Yun Wu Breakdown of academic impact, for papers by Ron Bose Breakdown of academic impact, for papers by Miriam Martini Breakdown of academic impact, for papers by Monica R. Maiello